Form 4: NeuroPace Director Joseph Lacob Increases Stake Through Compensation-Based Stock Acquisitions

NeuroPace Inc. Director Joseph Lacob has reported a series of stock acquisitions totaling 11,696 shares between June 2023 and June 2025, issued as compensation for his board service.

Summary

• Joseph Lacob, a Director at NeuroPace Inc. (NPCE), reported multiple acquisitions of common stock.
• The shares were issued to Mr. Lacob pursuant to NeuroPace's non-employee director compensation policy, in lieu of quarterly retainer fees.
• Between June 30, 2023, and June 21, 2025, Mr. Lacob acquired a total of 11,696 shares directly.
• The acquisitions occurred on various dates with prices ranging from $4.49 to $13.20 per share.
• As of the latest reported transaction on June 21, 2025, Mr. Lacob directly beneficially owned 12,080 shares of common stock.
• Additionally, Mr. Lacob indirectly beneficially owns 128,174 shares through Lacob Ventures LLC and 223,554 shares through LCT18 Investments, bringing his total beneficial ownership to 363,808 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the acquisitions are compensation-based and not open-market purchases, they still represent an increase in insider ownership, which generally signals confidence in the company's long-term prospects and aligns director interests with shareholders. There are no negative aspects reported in this specific filing.

Positives

• Increased direct ownership by a company director, Joseph Lacob, which can signal confidence in the company's future prospects.
• The consistent acquisition of shares, even if compensation-based, aligns the director's interests with those of shareholders.

Future Outlook

This Form 4 filing primarily reports past and scheduled future transactions related to director compensation and does not provide forward-looking statements or guidance on the company's operational or financial performance.

Industry Context

This filing is an insider transaction report for a director of NeuroPace Inc., a company operating in the medical device sector, specifically focusing on neuromodulation for epilepsy. The acquisitions reflect standard non-employee director compensation practices within the industry, where equity is often used to align director interests with long-term company performance.

Comparison to Industry Standards

• The practice of compensating non-employee directors with equity (shares in lieu of cash retainer fees) is a common and widely accepted corporate governance standard across the medical device and broader technology industries. This aligns director incentives with shareholder value creation.
• While specific comparable companies are not mentioned in the filing, companies like Medtronic (MDT), Boston Scientific (BSX), and Abbott Laboratories (ABT) also utilize equity-based compensation for their non-executive directors, reflecting a similar approach to corporate governance and incentive alignment.

Corporate Governance

Related Party Transactions

• The transactions involve the issuance of common stock by NeuroPace Inc. to its director, Joseph Lacob, as part of his compensation. This is a standard related-party transaction for director remuneration.

Stakeholder Impact

• Shareholders: Increased director ownership can be viewed positively as it aligns management interests with shareholder interests, potentially signaling confidence in the company's future.
• Employees: No direct impact mentioned, but a stable and confident board can contribute to overall company stability.

Key Dates

Keywords

NeuroPace Inc., NPCE, Joseph Lacob, SEC Form 4, Insider Trading, Stock Acquisition, Director Compensation, Beneficial Ownership, Medical Devices, Epilepsy Treatment